GSK 2878175

Drug Profile

GSK 2878175

Alternative Names: GSK-2878175

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Regulus Therapeutics
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 11 Nov 2016 Pharmacokinetics data from a preclinical study in Hepatitis C presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in Australia (PO, Tablet)
  • 07 Jul 2016 Phase-II clinical trials in Hepatitis C (Treatment-naive, Combination therapy) in Spain (PO) after July 2016 (EudraCT-2015-004702-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top